Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013 (2013), Article ID 348145, 7 pages
http://dx.doi.org/10.1155/2013/348145
Clinical Study

Ceruloplasmin and the Extent of Heart Failure in Ischemic and Nonischemic Cardiomyopathy Patients

Department of Cardiology, Second Affiliated Hospital, Zhejiang University, College of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang 310009, China

Received 22 March 2013; Revised 1 May 2013; Accepted 12 May 2013

Academic Editor: Giuseppe Valacchi

Copyright © 2013 Yifei Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Leeuwenburgh, J. E. Rasmussen, F. F. Hsu, D. M. Mueller, S. Pennathur, and J. W. Heinecke, “Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3520–3526, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. J. B. Bustamante, M. C. Mateo, J. Fernandez, B. de Quiros, and O. O. Manchado, “Zinc, copper and ceruloplasmin in arteriosclerosis,” Biomedicine Express, vol. 25, no. 7, pp. 244–245, 1976. View at Google Scholar · View at Scopus
  3. A. Reunanen, P. Knekt, and R. K. Aaran, “Serum ceruloplasmin level and the risk of myocardial infarction and stroke,” American Journal of Epidemiology, vol. 136, no. 9, pp. 1082–1090, 1992. View at Google Scholar · View at Scopus
  4. M. Mänttäri, V. Manninen, J. K. Huttunen et al., “Serum ferritin and ceruloplasmin as coronary risk factors,” European Heart Journal, vol. 15, no. 12, pp. 1599–1603, 1994. View at Google Scholar · View at Scopus
  5. K. Klipstein-Grobusch, D. E. Grobbee, J. F. Koster et al., “Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study,” British Journal of Nutrition, vol. 81, no. 2, pp. 139–144, 1999. View at Google Scholar · View at Scopus
  6. P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Elsherif, R. V. Ortines, J. T. Saari, and Y. J. Kang, “Congestive heart failure in copper-deficient mice,” Experimental Biology and Medicine, vol. 228, no. 7, pp. 811–817, 2003. View at Google Scholar · View at Scopus
  8. M. Correale, N. Daniele Brunetti, L. de Gennaro, and M. di Biase, “Acute phase proteins in atherosclerosis (Acute Coronary Syndrome),” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 6, no. 4, pp. 272–277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. Adelstein, T. L. Coombs, and B. L. Vallee, “Metalloenzymes and myocardial infarction—I. The relation between serum copper and ceruloplasmin and its catalytic activity,” The New England journal of medicine, vol. 255, no. 3, pp. 105–109, 1956. View at Google Scholar · View at Scopus
  10. A. Enbergs, A. Dorszewski, M. Luft et al., “Failure to confirm ferritin and caeruloplasmin as risk factors for the angiographic extent of coronary arteriosclerosis,” Coronary Artery Disease, vol. 9, no. 2-3, pp. 119–124, 1998. View at Google Scholar · View at Scopus
  11. A. Ziakas, S. Gavrilidis, E. Souliou et al., “Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina,” Angiology, vol. 60, no. 1, pp. 50–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. L. Fox, C. Mukhopadhyay, and E. Ehrenwald, “Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin,” Life Sciences, vol. 56, no. 21, pp. 1749–1758, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Weissman, R. D. Wochner, F. X. Mullins, A. Wynngate, and T. A. Waldmann, “Synthesis of plasma proteins by hepatectomized dogs,” The American journal of physiology, vol. 210, no. 1, pp. 128–132, 1966. View at Google Scholar · View at Scopus
  14. G. Ramadori, J. Van Damme, H. Rieder, and K. H. Meyer zum Buschenfelde, “Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1β and tumor necrosis factor-α,” European Journal of Immunology, vol. 18, no. 8, pp. 1259–1264, 1988. View at Google Scholar · View at Scopus
  15. B. Mazumder, C. K. Mukhopadhyay, A. Prok, M. K. Cathcart, and P. L. Fox, “Induction of ceruloplasmin synthesis by IFN-γ in human monocytic cells,” Journal of Immunology, vol. 159, no. 4, pp. 1938–1944, 1997. View at Google Scholar · View at Scopus
  16. E. J. Lewis, A. D. Sedgwick, and T. H. Hanahoe, “In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF,” Mediators of Inflammation, vol. 1, pp. 39–44, 1992. View at Google Scholar
  17. G. Engström, P. Lind, B. Hedblad, L. Stavenow, L. Janzon, and F. Lindgärde, “Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men,” Circulation, vol. 105, no. 22, pp. 2632–2637, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Shukla, J. Maher, J. Masters, G. D. Angelini, and J. Y. Jeremy, “Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?” Atherosclerosis, vol. 187, no. 2, pp. 238–250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Altamura, R. Squitti, P. Pasqualetti et al., “Ceruloplasmin/Transferrin system is related to clinical status in acute stroke,” Stroke, vol. 40, no. 4, pp. 1282–1288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Shiva, X. Wang, L. A. Ringwood et al., “Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis,” Nature Chemical Biology, vol. 2, no. 9, pp. 486–493, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Martin, T. Linden, D. M. Katschinski et al., “Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation,” Blood, vol. 105, no. 12, pp. 4613–4619, 2005. View at Publisher · View at Google Scholar · View at Scopus